<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Salicylamide <z:chebi fb="0" ids="24302">glucuronide</z:chebi> (SAMG) in 0-6 and 6-12 hours-urine specimens was determined after oral administration of salicylamide in 7 <z:mpath ids='MPATH_458'>normal</z:mpath> volunteers (NV), in 51 cases of various <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver diseases</z:e> and <z:hpo ids='HP_0002904'>hyperbilirubinemias</z:hpo>, and in 19 cases after drug administration, to predict the in vivo drug metabolism in man and its change by drugs </plain></SENT>
<SENT sid="1" pm="."><plain>Maximal <z:chebi fb="0" ids="24302">glucuronide</z:chebi> formation was obtained by 1.0 g of salicylamide administered to NV; thus, this dosage was used in the present study </plain></SENT>
<SENT sid="2" pm="."><plain>SAMG as percent of total salicylamide, the percent of SAMG, from 0-6 hours-urine specimens was high and constant in NV (71.3 +/- 8.3 (Mean +/- S.D.)) </plain></SENT>
<SENT sid="3" pm="."><plain>0-0.08% of the total salicylamide was confirmed as free salicylamide in 0-12 hours-urine specimens of NV </plain></SENT>
<SENT sid="4" pm="."><plain>The percent of SAMG of 0-6 hours-urine specimens was 57.2 +/- 8.6 in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo>, 66.6 +/- 10.9 in <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo>, and 48.6 +/- 10.7 in liver <z:hpo ids='HP_0001394'>cirrhosis</z:hpo> (mean +/- S.D.) </plain></SENT>
<SENT sid="5" pm="."><plain>Free salicylamide increased slightly in <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver diseases</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels tended to be inversely correlated with the percent of SAMG </plain></SENT>
<SENT sid="7" pm="."><plain>In most cases of <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e>, the percent of SAMG remained at a <z:mpath ids='MPATH_458'>normal</z:mpath> level </plain></SENT>
<SENT sid="8" pm="."><plain>The percent of SAMG in cases with <z:hpo ids='HP_0008282'>unconjugated hyperbilirubinemias</z:hpo> of other geneses were almost within <z:mpath ids='MPATH_458'>normal</z:mpath> limits </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="31314">Bucolome</z:chebi> and <z:chebi fb="1" ids="8069">phenobarbital</z:chebi> increased the percent of SAMG in patients with various <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver diseases</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>After <z:chebi fb="0" ids="28077">rifampicin</z:chebi> or phenytoin administration, the percent of SAMG of the patients with <z:e sem="disease" ids="C0041327" disease_type="Disease or Syndrome" abbrv="">lung tuberculosis</z:e> or <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> did not surpass that of NV </plain></SENT>
</text></document>